Your browser doesn't support javascript.
loading
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.
Chapman, Judith-Anne W; Bayani, Jane; SenGupta, Sandip; Bartlett, John M S; Piper, Tammy; Quintayo, Mary Anne; Virk, Shakeel; Goss, Paul E; Ingle, James N; Ellis, Matthew J; Sledge, George W; Budd, G Thomas; Rabaglio, Manuela; Ansari, Rafat H; Tozer, Richard; D'Souza, David P; Chalchal, Haji; Spadafora, Silvana; Stearns, Vered; Perez, Edith A; Gelmon, Karen A; Whelan, Timothy J; Elliott, Catherine; Shepherd, Lois E; Chen, Bingshu E; Taylor, Karen J.
Afiliação
  • Chapman JW; Canadian Cancer Trials Group Queen's University, Kitchener, Canada.
  • Bayani J; Ontario Institute for Cancer Research, Toronto, Canada.
  • SenGupta S; University of Toronto, Toronto, Canada.
  • Bartlett JMS; Queen's University, Kingston, Canada.
  • Piper T; University of Edinburgh, Edinburgh, United Kingdom.
  • Quintayo MA; University of Edinburgh, Edinburgh, United Kingdom.
  • Virk S; Ontario Institute for Cancer Research, Toronto, Canada.
  • Goss PE; Canadian Cancer Trials Group Queen's University, Kingston, Canada.
  • Ingle JN; Harvard University, Boston, MA.
  • Ellis MJ; Harvard University, Boston, MA.
  • Sledge GW; Progendis, Gaithersburg, MD.
  • Budd GT; Caris Life Sciences, Irving, TX.
  • Rabaglio M; Cleveland Clinic, Cleveland, OH.
  • Ansari RH; Inselspital Bern, Bern, Switzerland.
  • Tozer R; Indiana School of Medicine, South Bend, IN.
  • D'Souza DP; McMaster University, Hamilton, Canada.
  • Chalchal H; London Regional Health Science Centre, London, Canada.
  • Spadafora S; Alan Blair Cancer Center, Regina, Canada.
  • Stearns V; Algoma Regional Cancer Centre, Sault Ste Marie, Canada.
  • Perez EA; Weill Cornell Medicine, New York, NY.
  • Gelmon KA; Harvard University, Boston, MA.
  • Whelan TJ; Mayo Clinic, Redwood City, CA.
  • Elliott C; University of British Columbia, Vancouver, Canada.
  • Shepherd LE; McMaster University, Hamilton, Canada.
  • Chen BE; Canadian Cancer Trials Group Queen's University, Kingston, Canada.
  • Taylor KJ; Canadian Cancer Trials Group Queen's University, Kingston, Canada.
J Clin Oncol ; : JCO2400835, 2024 Jun 02.
Article em En | MEDLINE | ID: mdl-38824432
ABSTRACT

PURPOSE:

ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes.

METHODS:

MA.27 (ClinicalTrials.gov identifier NCT00066573) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (≤-1; (-1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance P < .05.

RESULTS:

Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis

results:

2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS (P < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated (P = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS (P = .001) in models with ER.

CONCLUSION:

Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ ≤-1.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá